RxDoctor Payments Data

Henry Tan, MD

Clinical Cardiac Electrophysiology · Queensbury, NYNPI 1194744318

Payments from drug & device makers

$4,067in general payments, 2019–2025

Across 60 payments — averaging $67.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$392
  • Baxter Healthcare$202
  • Novartis$70
  • Pfizer$69
  • Sanofi-aventis U.S. LLC$58
  • plus $123 from 6 others

What the payments were for

  • Travel & lodging$1,65750%
  • Food & beverage$1,65950%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,067 in reported general payments places this provider in the 15th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$81,261
Medicare patients
481
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$115,493
EntrestoSacubitril/Valsartan33$50,131
MultaqDronedarone Hcl19$18,993
XareltoRivaroxaban13$13,739
Amiodarone Hcl113$2,364
Metoprolol Succinate157$1,975
Mexiletine Hcl13$1,158
Digoxin25$766
Atorvastatin Calcium81$712
Sotalol AfSotalol Hcl18$581
SotalolSotalol Hcl26$550
Flecainide Acetate13$546
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$522
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen61$429
ClopidogrelClopidogrel Bisulfate26$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$115,49386 claims
NovartisEntresto$70$50,13133 claims
Sanofi-aventis U.S. LLCMultaq$58$18,99319 claims
Johnson & JohnsonXarelto$29$13,73913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in Queensbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →